RT Journal Article SR Electronic T1 Severe cholestasis due to azathioprine in Behcet’s disease JF BMJ Case Reports JO BMJ Case Reports FD BMJ Publishing Group Ltd SP e226340 DO 10.1136/bcr-2018-226340 VO 12 IS 3 A1 Kadir Gisi A1 Murat Ispiroglu A1 Bulent Kantarceken A1 Hamide Sayar YR 2019 UL http://casereports.bmj.com/content/12/3/e226340.abstract AB Azathioprine (AZA) is an immunosuppressive drug that is widely used in the treatment of autoimmune diseases. Although AZA is used widely, many studies reported that AZA-related hepatotoxicity is rather rare. We aimed to present a case with severe cholestatic hepatitis due to AZA use for Behcet’s disease. Three weeks after starting AZA for the treatment of uveitis, the patient was admitted to our clinic with cholestasis and constitutional symptoms. In liver biopsy, findings were in accordance with drug reaction, and the AZA treatment was stopped. After 2 months, bilirubin levels and liver tests results became normal. As a result, given that AZA may cause severe cholestasis, the drug should be stopped if idiosyncrasy or hypersensitivity develops. If there is a debate in the diagnosis, histopathological evaluation of the liver would be the major issue because of the correct diagnosis of the drug toxicity and excluding other aetiologies.